Halozyme Therapeutics, Inc. — Q2 2015 Form 10-Q
Reporting period: Three and six months ended June 30, 2015. Financial statement amounts are in millions of dollars unless otherwise noted. Halozyme develops oncology therapies, including PEGPH20, and licenses its Enhanze technology for subcutaneous drug delivery.
Financial performance and liquidity
| Metric | Q2 2015 | Q2 2014 | First half 2015 | First half 2014 |
|---|---|---|---|---|
| Total revenue | $43.4 | $18.4 | $62.1 | $30.4 |
| Operating income (loss) | $4.2 | $(14.9) | $(9.7) | $(40.2) |
| Net income (loss) | $3.0 | $(16.3) | $(12.1) | $(42.8) |
| Net income (loss) per share | $0.02 | $(0.13) | $(0.10) | $(0.35) |
| Operating cash flow | Not presented quarterly | Not presented quarterly | $(4.9) | $(33.4) |
- Q2 revenue grew substantially, with $23.0 million of AbbVie license revenue recognized under a new collaboration. Q2 royalties were $6.4 million, versus $1.7 million, primarily reflecting Roche product sales; product sales were $12.3 million, versus $9.5 million.
- First-half revenue included $13.2 million in royalties, versus $2.5 million, and $26.7 million in collaborative-agreement revenue, versus $9.8 million. Management attributed higher revenue chiefly to royalties and license fees; research-service reimbursements declined.
- Q2 operating margin was approximately 9.8%, compared with a negative margin in the prior-year quarter. The Q2 profit followed the recognition of AbbVie’s upfront license fee; first-half results remained loss-making.
- At June 30, cash and cash equivalents were $67.8 million and marketable securities were $72.9 million, totaling $140.7 million. Management said these resources should fund operations for at least 12 months.
- First-half net cash used in operations was $4.9 million. Cash increased by $6.4 million from year-end, including $10.9 million of financing proceeds, primarily from equity-plan issuances.
- Debt was approximately $49.8 million net of discount. The loan bears 7.55% interest, carries a $4.25 million final payment, and matures January 1, 2018. Principal repayments are scheduled to begin in February 2016; the company reported compliance with material covenants.
- Current assets were $168.4 million and current liabilities $35.0 million. Deferred revenue totaled $51.7 million, including $45.3 million classified as long-term.
Material changes versus comparable periods
- Q2 revenue rose from $18.4 million to $43.4 million, while net results improved from a $16.3 million loss to $3.0 million of income. The new AbbVie license fee was a major contributor and should not be assumed to recur at the same level.
- First-half revenue more than doubled, and the net loss narrowed to $12.1 million from $42.8 million. Operating cash use also declined materially from $33.4 million to $4.9 million.
- First-half R&D expense fell to $37.9 million from $40.1 million, but PEGPH20 spending increased to $29.9 million from $14.0 million as clinical activity expanded. Spending on the ultrafast insulin program declined substantially.
- First-half financing proceeds were $10.9 million, compared with $111.2 million in 2014, which included a $107.7 million public offering.
Outlook, commentary, and risks
- Management anticipated 2015 net cash burn of approximately $20 million to $30 million, depending on clinical and preclinical progress, manufacturing scale-up, and collaboration milestones and royalties. It expected R&D spending to increase with PEGPH20 development and SG&A to rise moderately. No specific revenue or earnings guidance was provided.
- PEGPH20 was in Phase 2 testing for metastatic pancreatic cancer and Phase 1b testing for non-small cell lung cancer. Management planned a Phase 3 pancreatic-cancer study focused on tumors with high hyaluronan levels, with progression-free and overall survival as co-primary endpoints. FDA feedback indicated an approved companion diagnostic strategy was required before Phase 3 initiation; EMA provided scientific advice in June.
- Interim Stage 1 Phase 2 data in high-hyaluronan patients showed longer median progression-free survival and a higher response rate with PEGPH20 plus chemotherapy than with chemotherapy alone. These were interim findings from a subgroup, and the filing notes safety and benefit-risk considerations remain important.
- Thromboembolic events prompted a 2014 clinical hold and protocol revisions, including patient-risk exclusions and anticoagulant prophylaxis. The company continued monitoring; the study could be halted again if event rates do not meet protocol criteria. Thromboembolic risk is a significant clinical and regulatory uncertainty.
- In June, Halozyme entered an AbbVie collaboration covering up to nine targets and received $23.0 million for one specified target. Additional development, regulatory, and sales-based payments and royalties are contingent on future events.
- Key risks include clinical efficacy and safety, regulatory approval and companion-diagnostic development, reliance on collaborators and contract manufacturers, potential anti-rHuPH20 antibodies, limited profitability history, future financing needs, and debt covenants. The company reported no legal proceedings expected to have a material adverse effect.
Important facts for investors to verify
- How much of reported revenue and Q2 profit reflects nonrecurring upfront license fees versus product sales and recurring royalties.
- Whether the PEGPH20 Phase 3 study and companion diagnostic can proceed, and whether efficacy and thromboembolic safety findings are confirmed in the full trial population.
- Whether royalty growth from Roche and commercial uptake of HYQVIA translate into sustained cash generation.
- Actual cash burn versus the $20 million–$30 million 2015 estimate, and liquidity needs beyond management’s stated 12-month runway.
- Debt repayment requirements, the final payment, covenant compliance, and any potential need for additional or dilutive financing.